Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.18 USD
0.00 (-1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.18 0.00 (0.61%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMEarnings News For MTNB
-
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
-
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
-
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
-
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q4 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
-
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates
-
Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know